CD22 and acute lymphoblastic leukemia: Motivated by the success of Mylotarg, a similar immunoconjugate targeting CD22, Inotuzumab ozogamicin, was recently approved as monotherapy for adults with r/r B-cell precursor CD22-positive acute lymphoblastic leukemia (ALL).